Primary adrenal insufficiency – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:06 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Primary adrenal insufficiency – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Quality of Life in Patients Aged 16-80 with Primary Adrenal Insufficiency Using Hydrocortisone (Plenadren) and Cortisone https://clinicaltrials.eu/trial/study-on-quality-of-life-in-patients-aged-16-80-with-primary-adrenal-insufficiency-using-hydrocortisone-plenadren-and-cortisone/ Wed, 29 Apr 2026 15:00:56 +0000 https://clinicaltrials.eu/trial/study-on-quality-of-life-in-patients-aged-16-80-with-primary-adrenal-insufficiency-using-hydrocortisone-plenadren-and-cortisone/ This clinical trial is focused on studying a condition known as Primary Adrenal Insufficiency (PAI). This is a disorder where the adrenal glands do not produce enough hormones, which are crucial for various bodily functions. The study will compare two treatments: Plenadren 20 mg modified-release tablets and Cortison 25 mg tablets. Both medications are forms of hormone replacement therapy, with Plenadren containing hydrocortisone and Cortison containing cortisone. These treatments are designed to help manage the symptoms of PAI by supplementing the hormones that the adrenal glands are not producing sufficiently.

The purpose of this study is to investigate the differences in health-related quality of life for patients receiving these treatments. Participants in the study will be newly diagnosed with PAI and will be between the ages of 16 and 80. The study will follow participants from the time of diagnosis and then at 1, 6, and 12 months to assess how each treatment affects their quality of life. This will help determine which treatment might offer better outcomes for patients in terms of their daily well-being and overall health.

Throughout the study, various health indicators will be monitored, including blood pressure, body weight, and cholesterol levels, among others. Additionally, the study will look at hormone levels, sleep patterns, and cognitive function to provide a comprehensive view of how each treatment impacts the body. The study will also track any adverse events or symptoms related to adrenal crises to ensure patient safety. The trial is expected to conclude by February 2027.

]]> Study on the Tolerability and Acceptance of Oral Hydrocortisone for Children with Adrenal Hyperplasia or Adrenal Insufficiency https://clinicaltrials.eu/trial/study-on-the-tolerability-and-acceptance-of-oral-hydrocortisone-for-children-with-adrenal-hyperplasia-or-adrenal-insufficiency/ Wed, 29 Apr 2026 14:58:26 +0000 https://clinicaltrials.eu/trial/study-on-the-tolerability-and-acceptance-of-oral-hydrocortisone-for-children-with-adrenal-hyperplasia-or-adrenal-insufficiency/ This clinical trial is focused on studying the tolerability and acceptance of two oral medications containing hydrocortisone for children. The diseases being studied include adrenal hyperplasia, primary adrenal insufficiency, and panhypopituitarism, which are conditions that affect hormone production in the body. The treatment involves two different formulations of hydrocortisone, which is a medication used to replace hormones that the body is not producing in sufficient amounts.

The purpose of the study is to evaluate how well children tolerate and accept these two hydrocortisone formulations. The study will involve children aged 6 to 17 years who have been diagnosed with one of the mentioned conditions. Participants will receive one of the two hydrocortisone formulations prepared by the Hospital Pharmacy Service. The study will assess how the children respond to the medication over a period of time, focusing on how acceptable the medication is in terms of taste and ease of use.

Throughout the study, the children will be monitored to ensure their safety and to gather information on how they react to the medication. The study aims to provide valuable insights into the best ways to administer hydrocortisone to children with these conditions, ensuring that the treatment is both effective and easy for them to take.

]]>